Genfit is a Lille-based biopharmaceutical company that has spent more than two decades developing treatments for metabolic liver diseases — and recently achieved a landmark regulatory approval that vindicates both the company’s scientific strategy and France 2030’s investment in liver disease research. Elafibranor, Genfit’s lead compound, received European Medicines Agency (EMA) approval in August 2024 as Iqirvo for the treatment of primary biliary cholangitis (PBC), followed by FDA approval. With a commercialization partnership with Ipsen providing sales force and distribution, Genfit has transitioned from a development-stage biotech into a company with an approved, revenue-generating drug — and a pipeline of additional liver disease candidates backed by France 2030 health innovation funding.
Company Overview
Founded in 1999 and listed on Euronext Paris (and Nasdaq until delisting in 2022), Genfit emerged from the academic research environment of the Institut Pasteur de Lille and the University of Lille biological sciences community. The Lille biotech ecosystem — which also includes Institut Mérieux-affiliated companies, BioMérieux’s industrial microbiology operations, and the Institut Pasteur regional network — benefits from France 2030’s health cluster investment that targets geographic distribution of French biotech capability beyond Paris and the Île-de-France cluster.
Genfit’s scientific focus on nuclear receptors and metabolic liver disease placed the company in a niche that has become increasingly important: non-alcoholic steatohepatitis (NASH, now called metabolic dysfunction-associated steatohepatitis, MASH), primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC) represent diseases with large unmet medical needs and limited treatment options. The metabolic liver disease epidemic — driven by obesity, type 2 diabetes, and alcohol consumption patterns — means the addressable patient population is growing globally.
The €300 million+ in clinical investment Genfit has made over 25 years reflects the capital intensity of drug development in complex metabolic and fibrotic liver disease. France 2030 and its predecessor programmes d’investissements d’avenir (PIA) provided a structural component of this funding, recognizing that France’s research excellence in metabolic disease biology (anchored at Institut Pasteur, INSERM, and the Lille academic medical center) should translate into French pharmaceutical products.
France 2030 Health Funding & Scientific Context
Genfit’s France 2030 alignment operates at multiple levels. The plan’s health and biotherapy pillar — with dedicated funding for bioproduction, innovative medicines, and digital health — explicitly targets the development of France’s pharmaceutical innovation capacity. Genfit represents the established end of this pipeline: a company that has completed Phase 3 clinical development and achieved regulatory approval, demonstrating that French-originated drug discovery can produce globally approved medicines.
The bioproduction dimension of France 2030 is relevant to Genfit’s manufacturing strategy. France 2030 committed €1 billion to building French biomanufacturing capacity — ensuring that French drug discoveries are manufactured in France rather than at Asian contract manufacturers. Genfit’s commercialization of Iqirvo raises the question of manufacturing sovereignty: as Ipsen commercializes elafibranor globally, the extent to which active pharmaceutical ingredient (API) and drug product manufacturing occurs in France matters for France 2030’s industrial policy objectives.
INSERM and CNRS-affiliated research continues to collaborate with Genfit on liver disease biology, providing academic research access that would cost multiples more if conducted entirely in commercial settings. This academic-industry interface is a structural advantage of France’s research ecosystem that France 2030 explicitly seeks to strengthen.
Technology & Clinical Portfolio
Genfit’s pipeline centers on nuclear receptor modulators and biomarkers for liver disease diagnosis and treatment.
Elafibranor (Iqirvo) — PPAR alpha/delta agonist: The lead compound is a dual PPAR alpha/delta agonist — a nuclear receptor modulator that activates peroxisome proliferator-activated receptors involved in fatty acid oxidation, inflammation, and fibrosis regulation. In PBC, a chronic cholestatic liver disease where progressive bile duct destruction leads to cirrhosis, elafibranor demonstrated significant improvement in biochemical response in the ELATIVE Phase 3 trial. EMA approved Iqirvo in August 2024 as a second-line treatment for PBC in adults with inadequate response or intolerance to ursodeoxycholic acid (UDCA), the standard first-line therapy. FDA approval followed, establishing Genfit as a company with a marketed product in a rare liver disease with $1B+ peak sales potential.
Ipsen Partnership — Commercial Execution: Genfit licensed ex-French commercialization rights to Ipsen for €120 million upfront plus sales milestones. Ipsen brings established rare disease commercial infrastructure in the US, Europe, and Asia — markets where Genfit’s 200-person organization could not build commercial operations economically. This partnership model — French biotech discovers and develops, established pharmaceutical partner commercializes — is the standard French biotech exit/partnership template. The upfront payment provided Genfit with capital to fund continued pipeline development without dilutive equity raises.
NASH/MASH Pipeline: Despite the 2019 Phase 3 RESOLVE-IT trial failure in NASH (the trial missed its primary endpoint), Genfit maintained a NASH pipeline. The MASH space has become more active since resmetirom (Madrigal Pharmaceuticals) received FDA approval in 2024 — the first approved MASH treatment — validating the field and potentially creating combination treatment opportunities. Genfit continues development of compounds and biomarkers for MASH.
NASHnext — Liquid Biopsy Diagnostics: Genfit developed NASHnext, a blood-based diagnostic panel for non-invasive NASH assessment using biomarkers that correlate with liver histology. This diagnostic asset positions Genfit at the intersection of therapeutics and companion diagnostics — a combination that is strategically valuable as payers increasingly require biomarker-guided treatment decisions.
Competitive Landscape
In PBC specifically, Genfit’s Iqirvo competes with Intercept Pharmaceuticals’ obeticholic acid (Ocaliva, a FXR agonist) and with Ipsen’s own cilofexor/tropifexor combinations in development. The PBC market is relatively concentrated — approximately 100,000-130,000 diagnosed patients in the US, 150,000 in Europe — with pricing typically in the $50,000-$150,000 annual treatment range for rare disease indications.
The MASH/NASH space is more contested, with multiple large pharmaceutical companies (Novo Nordisk, Boehringer Ingelheim, Madrigal) pursuing GLP-1-based and other approaches. Genfit’s nuclear receptor expertise provides scientific differentiation but the commercial resources of large pharma competitors create execution risk.
Investor Perspective
Genfit has transformed from a speculative development-stage biotech into a company with an approved, partnered product and pipeline optionality. The Ipsen deal economics — €120 million upfront, milestones, royalties — provide near-term revenue certainty while elafibranor’s commercial trajectory unfolds.
The investment thesis centers on: Iqirvo’s commercial uptake in PBC (second-line market, competing with obeticholic acid); potential label expansion into first-line PBC; MASH pipeline value as the field validates; and NASHnext diagnostic commercial potential. The key risk is PBC market size — rare disease approval is a significant milestone but peak sales are bounded by patient population.
For France 2030 health portfolio investors, Genfit represents proof that France’s metabolic disease research excellence translates into globally approved drugs — the ultimate validation of France 2030’s health innovation investment thesis.
Related Companies
- Sanofi — France’s largest pharmaceutical company, industry context
- bioMérieux — French diagnostics leader, Lille ecosystem peer
- Ipsen — Genfit’s commercialization partner for Iqirvo
- OSE Immunotherapeutics — French clinical-stage biotech, peer company
- Cellectis — French gene therapy company, France 2030 biotech peer